Immune-mediated (IM) adverse drug reactions (ADRs) are an underrecognized source of
preventable morbidity, mortality, and cost. Increasingly, genetic variation in the HLA loci is …

Most immune-mediated adverse drug reactions (IM-ADRs) involve the skin, and many have
additional systemic features. Severe cutaneous adverse drug reactions (SCARs) are an …

Resolving conflict of interest The Joint Task Force on Practice Parameters (JTFPP) is
committed to ensuring that all guidelines are based on the best scientific evidence at the …

Polygonum multiflorum (PM) is a well‐known Chinese herbal medicine that has been
reported to induce inflammation‐associated idiosyncratic liver injury. This study aimed to …

Background Vancomycin is a prevalent cause of the severe hypersensitivity syndrome drug
reaction with eosinophilia and systemic symptoms (DRESS), which leads to significant …

Drug reaction with eosinophilia and systemic symptoms (DReSS), also known as drug-
induced hypersensitivity syndrome (DiHS), is a severe, systemic, T cell mediated drug …

The immunological mechanisms driving delayed hypersensitivity reactions (HSRs) to drugs
mediated by drug-reactive T lymphocytes are exemplified by several key examples and their …

Adverse drug reactions (ADR) can be broadly categorised as either on‐target or off‐target.
On‐target ADRs arise as a direct consequence of the pharmacological properties of the drug …

Delayed immune-mediated adverse drug reactions (IM-ADRs) are defined as reactions
occurring more than 6 hours after dosing. They include heterogeneous clinical phenotypes …

Background The use of in vivo and ex vivo diagnostic tools for delayed immune-mediated
adverse drug reactions is currently ill defined. Objective To determine whether the …